Decitabine for the treatment of acute myeloid leukemia

Bibliography

• American Cancer Society. Cancer facts and figures 2013. American Cancer Society, Atlanta, Ga; 2013. Available from: http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013 [Last accessed 17 April 2013]
   Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2011). Available from: www.seer.cancer.gov/popdata National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch 2013
   Google Scholar
• Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012;97:1916-24
   PubMed Web of Science ®Google Scholar
• Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666-7
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-59
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235-48
   PubMed Web of Science ®Google Scholar
• Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841-51
   PubMed Web of Science ®Google Scholar
• Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-17
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36
   PubMed Web of Science ®Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a southwest oncology group/eastern cooperative oncology group study. Blood 2000;96:4075-83
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-33
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-5
   PubMed Web of Science ®Google Scholar
• Büchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009;27:61-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090-8
   PubMed Web of Science ®Google Scholar
• Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995;332:1671-7
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Sergio A, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74
   PubMed Web of Science ®Google Scholar
• Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006;108:63-73
   PubMed Web of Science ®Google Scholar
• Egger G, Gangning L, Aparicio A, et al. Epigenetics in human disease and prospects for epignentic therapy. Nature 2004;429:457-63
   PubMed Web of Science ®Google Scholar
• Issa JPJ, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 1997;11(Suppl 1):S7-S11
   PubMed Web of Science ®Google Scholar
• Melki JR, Clark SJ. DNA methylation changes in leukaemia. Semin Cancer Biol 2002;12:347-57
   PubMed Web of Science ®Google Scholar
• Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998;12:845-59
   PubMed Web of Science ®Google Scholar
• Herman JG, Civin CI, Issa JP, et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997;57:837-41
   PubMed Web of Science ®Google Scholar
• Jones PA, Taylor SM, Mohardas T, Shapiro LI. Cell cycle specific reactivation of an inactive X-chromosome locus by 5-aza-2′-deoxycytidine. Proc Natl Acad Sci USA 1982;79:1215-19
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: acute myeloid leukemia v 2. 2013. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Pliml J, Sorm F. Synthesis of 2-deoxy-D-ribofuranosyl-5-azacytosine. Collect Czech Chem Commun 1964;29:2576-7
   Web of Science ®Google Scholar
• Sorm F, Vesely J. Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 1968;15:339-43
   PubMed Web of Science ®Google Scholar
• Rivard GE, Momparler RL, Demers J, et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 1981;5:452-62
   Google Scholar
• van Groeningen C, Leyva A, O’Brien A, et al. Phase I and pharmacokinetic study of 5-aza-2’-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 1986;46:4831-6
   PubMed Web of Science ®Google Scholar
• Bouchard J, Momparler RL. Incorporation of 5-Aza-2′-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol 1983;24:109-14
   PubMed Web of Science ®Google Scholar
• Wilson VL, Jones PA, Momparler RL. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 1983;43:3493-6
   PubMed Web of Science ®Google Scholar
• Pinto A, Attadia V, Fusco A, et al. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984;64:922-9
   PubMed Web of Science ®Google Scholar
• Limonta M, Colombo T, Damia G, et al. Cytotoxic activity and mechanism of action of 5-aza-2’-deoxycytidine in human CML cells. Leuk Res 1993;17:977-82
   PubMed Web of Science ®Google Scholar
• Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40
   PubMed Web of Science ®Google Scholar
• Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008;123:8-13
   PubMed Web of Science ®Google Scholar
• Lin KT, Momparler RL, Rivard GE. High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine. J Pharm Sci 1981;70:1228-32
   PubMed Web of Science ®Google Scholar
• Tomankova H, Zyka J. Study of the time dependence of the stability of 5-aza-2′-deoxycytidine in acid medium. Microchem J 1980;25:281-8
   Google Scholar
• van Groeningen CJ, Leyva A, O'Brien AM, et al. Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 1986;46:4831-6
   PubMed Web of Science ®Google Scholar
• Product information: DACOGEN(R) injection, decitabine injection. Eisai, Inc, Woodcliff Lake, NJ; 2010
   Google Scholar
• Amanda F, Cashen AF, Shah AK, et al. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 2008;61:759-66
   PubMed Web of Science ®Google Scholar
• Chabot GG, Rivard GE, Momparler RL. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2′-deoxycytidine in rabbits and dogs. Cancer Res 1983;43:592-7
   PubMed Web of Science ®Google Scholar
• Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2’-deoxycytidine in patients with acute leukemia. Pharmacol Ther 1985;30:277-86
   PubMed Web of Science ®Google Scholar
• Zagonel V, Lo Re G, Marotta G, et al. 5-Aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 1993;7(Suppl 1):30-5
   PubMed Web of Science ®Google Scholar
• Wijermans PW, Krulder JW, Huijgens PC, et al. Continuous infusion of low-dose 5-Aza-2’-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997;11:1-5
   PubMed Web of Science ®Google Scholar
• Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-62
   PubMed Web of Science ®Google Scholar
• Wijermans P, Luebbert M, Verhoef G. Low dose decitabine for elderly high risk MDS patients: who will respond [abstract]. Blood 2002;96:355
   Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-803
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-4
   PubMed Web of Science ®Google Scholar
• WijerMans P, Suciu S, Baila L, et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy:final results of the randomized phase III study (06011) of the EORTC leukemia and german MDS study groups [abstract]. Blood 2008;112:226
   Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-7
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenber PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25
   PubMed Web of Science ®Google Scholar
• Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27:3842-8
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Steensma DP. Myelodysplastic syndrome patients obtaining a cytogenetic response to outpatient decitabine experience improved hematological responses and longer survival: additional analyses from the ADOPT trial [abstract]. Blood 2009;114:3817
   Google Scholar
• Kantarjian HM, O’Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007;109:1133-7
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32
   PubMed Web of Science ®Google Scholar
• Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis. Haematologica 2010;95:303-10
   PubMed Web of Science ®Google Scholar
• Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2’-deoxycytidine in patients with acute leukemia. Pharmacol Ther 1985;30:277-86
   PubMed Web of Science ®Google Scholar
• Petti MC, Mandelli F, Zagonel V, et al. Pilot study of 5-aza-2’-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 1993;7(Suppl 1):36-41
   PubMed Web of Science ®Google Scholar
• Willemze R, Archimbaud E, Muus P. Preliminary results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia 1993;7(Suppl 1):49-50
   PubMed Web of Science ®Google Scholar
• Willemze R, Suciu S, Archimbaud E, et al. A randomized phase II study on the effects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 1997;11(Suppl 1):24-7
   PubMed Web of Science ®Google Scholar
• Issa JPJ, Saba HI, Garcia-Manero G, et al. Decitabine in older patients with acute myelogenous leukemia (AML) [abstract]. J Clin Oncol 2007;25:7021
   Google Scholar
• Danilov AV, Smith H, Relias V, et al. Outpatient decitabine in elderly patients with acute myeloid leukemia (AML) [abstract]. Blood 2009;114:4144
   Google Scholar
• Cashen AF, Schiller GJ, O'Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28:556-61
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30:2670-7
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012;120:4840-5
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010;107(16):7473-8
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-19
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33
   PubMed Web of Science ®Google Scholar
• Garzon R, Heaphy CE, Havelange V, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009;114:5331-41
   PubMed Web of Science ®Google Scholar
• Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma 2013; Epub ahead of print
   Google Scholar
• Yang H, Hoshino K, Sanchez-Gonzalez B, et al. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 2005;29:739-48
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Tambaro FP, Bekele NB, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 2012;30:2204-10
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266-9
   PubMed Web of Science ®Google Scholar
• Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-91
   PubMed Web of Science ®Google Scholar
• Issa JP, Castoro R, Ravandi-Kashani F, et al. Randomized phase II study of combined epigenetic therapy: decitabine vs. decitabine and valproic acid in MDS and AML [abstracts]. Blood 2008;112:228
   Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-9
   PubMed Web of Science ®Google Scholar
• Ravandi F, Faderl S, Thomas D, et al. Phase I study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis leukemia [abstract]. Blood 2007;110:897
   Web of Science ®Google Scholar
• Kirschbaum M, Gojo I, Goldberg SL, et al. Phase I study of vorinostat in combination with decitabine in patients with relapsed or newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome [abstract]. Blood 2008;112:3651
   Google Scholar
• Liu S, Liu Z, Xie Z, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008;111:2364-73
   PubMed Web of Science ®Google Scholar
• Blum W, Schwind S, Somayeh S, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012;119:6025-31
   PubMed Web of Science ®Google Scholar
• Faderl S, Ravandi F, Huang X, et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 2012;118:4471-7
   PubMed Web of Science ®Google Scholar
• Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991;78:2520-6
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235-48
   PubMed Web of Science ®Google Scholar
• Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25:1908-15
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, et al. Eastern Cooperative Oncology. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-85
   PubMed Web of Science ®Google Scholar
• Lang K, Earle C, Foster T, et al. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging 2006;22:943-55
   Web of Science ®Google Scholar
• de Lima M, Ghaddar H, Pierce S, et al. Treatment of newly-diagnosed acute myelogenous leukemia in patients aged 80 years and above. Br J Haematol 1996;93:89-93
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Burnett A, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 11 trial. Blood 2001;98:1302-11
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114-24
   PubMed Web of Science ®Google Scholar
• Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 2007;13:4225-32
   PubMed Web of Science ®Google Scholar
• Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 2011;118:1472-80
   PubMed Web of Science ®Google Scholar